Prospective Cohort Study on Thermal Ablation of Malignant Liver Tumors

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-110
SponsorLeiden University Medical Center

About this trial

The endpoint of this study is to develop and validate algorithms, using artificial intelligence and machine learning, to optimize patient selection, treatment planning, treatment evaluation and outcome prediction in patients undergoing thermal ablation of a malignant liver tumor. The long-term objective is to establish thermal ablation as the treatment of choice for the vast majority of patients with a primary or secondary liver tumor by development of an accessible workflow that can be widely implemented in different centers performing thermal ablation. Over a time span of at least four years, data will be collected prospectively, encompassing patient information, tumor characteristics, and treatment details. Additionally, pre-, intra-, and post-procedural imaging will be systematically gathered.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

18 years or above

Candidate for percutaneous thermal liver ablation as discussed in a multidisciplinary tumorboard (MDT)

Informed consent

Disqualifiers

Patients lacking capacity to give informed consent.

Trial population

All patients diagnosed with one or more primary or secondary liver malignancy who are candidates for thermal liver ablation as discussed in a multidisciplinary tumour board.

Trial design

Design model

Cohort

Time perspective

Other

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Efficacy as assessed by local recurrence

Time frame
Throughout the entire four-year study period
2

Efficacy as assessed by time-to-recurrence

Time frame
Throughout the entire four-year study period
3

Efficacy as assessed by disease-free-survival

Time frame
Throughout the entire four-year study period
4

Efficacy as assessed by overall survival

Time frame
Throughout the entire four-year study period

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Leiden University Medical Center

Lead sponsor

Philips Healthcare

Collaborator

European Commission

Collaborator